Intersect ENT Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc., an innovator in treatment solutions for ear, nose and throat clinicians and their patients, today announced the start of RESOLVE, a prospective, randomized, blinded, multi-center clinical trial to study the use of the company’s newest steroid delivery implant for patients with chronic sinusitis.

Back to news